Evidence map›Paper›PMID 32531179›Full record

ReviewExpert review of anticancer therapy2020

The current clinical approach to newly diagnosed uterine cancer.

Olga T Filippova, Mario M Leitao

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Expert review of anticancer therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05998811 (Exploring Uterine Cancer Clinical Trials - Revealing Participation Patterns in Individuals With Uterine Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05998811 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Exploring Uterine Cancer Clinical Trials - Revealing Participation Patterns in Individuals With Uterine Cancer

TypeobservationalSponsorPower Life Sciences Inc.Ran2024 to 2026Enrolled500ConditionsUterine Cancer
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Olga T FilippovaGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY, USA.
Mario M LeitaoGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY, USA.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionUterine cancer is the most common gynecologic malignancy, although fortunately, 75% of women present with early-stage disease. A major area of controversy regarding the management of the disease concerns postoperative therapy for both women with early- and advanced-stage endometrial carcinoma. Here, we review landmark evidence that can help guide clinical decision-making in the treatment of women diagnosed with endometrial cancer. AREAS COVERED: In this review, we present the latest data driving decisions for both surgical management and postoperative therapy for women with endometrial carcinoma. Areas discussed include surgical staging, with a specific discussion on the role of sentinel lymph node mapping, and postoperative therapy, ranging from the data supporting observation for women with early-stage, low-risk disease to combination therapy for women with advanced disease. Less common histologies, such as serous and clear cell carcinoma, as well as carcinosarcoma, will also be covered. Furthermore, a section of the paper is dedicated to the current state of fertility-sparing surgery. EXPERT OPINION: We suggest several approaches for deciding on adjuvant therapy, based on stage and histology, after comprehensive surgical staging. The role that endometrial cancer molecular subtypes will play on postoperative therapy remains to be fully investigated.

Indexed as

Clinical Decision-MakingCombined Modality TherapyEndometrial NeoplasmsFemaleHumansNeoplasm StagingSentinel Lymph Node BiopsyUterine Neoplasmsadjuvant therapycarcinosarcomaclear cellEndometrial cancerendometrioidfertility-sparing treatmentsentinel lymph node mappingseroussurgical staging

Identifiers

PMID32531179
PMCPMC7416456
OpenAlexW3034334260

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.